BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen F, Wang S, Wei Y, Wu J, Huang G, Chen J, Shi J, Xia J. Norcantharidin modulates the miR-30a/Metadherin/AKT signaling axis to suppress proliferation and metastasis of stromal tumor cells in giant cell tumor of bone. Biomedicine & Pharmacotherapy 2018;103:1092-100. [DOI: 10.1016/j.biopha.2018.04.100] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Zheng J, Wang JJ, Ma HM, Shen MQ, Qian ZM, Bao YX. Norcantharidin down-regulates iron contents in the liver and spleen of lipopolysaccharide-treated mice. Redox Rep 2022;27:119-27. [PMID: 35735222 DOI: 10.1080/13510002.2022.2088011] [Reference Citation Analysis]
2 Yue J, Sun W, Li S. Denosumab Versus Zoledronic Acid in Cases of Surgically Unsalvageable Giant Cell Tumor of Bone: A Randomized Clinical Trial. Journal of Bone Oncology 2022. [DOI: 10.1016/j.jbo.2022.100441] [Reference Citation Analysis]
3 Du LJ, Feng YX, He ZX, Huang L, Wang Q, Wen CP, Zhang Y. Norcantharidin ameliorates the development of murine lupus via inhibiting the generation of IL-17 producing cells. Acta Pharmacol Sin 2022;43:1521-33. [PMID: 34552214 DOI: 10.1038/s41401-021-00773-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Liu Z, Zhao L, Tan X, Wu Z, Zhou N, Dong N, Zhang Y, Yin T, He H, Gou J, Tang X, Gao S. Preclinical evaluations of Norcantharidin liposome and emulsion hybrid delivery system with improved encapsulation efficiency and enhanced antitumor activity. Expert Opin Drug Deliv 2022. [PMID: 35385376 DOI: 10.1080/17425247.2022.2063834] [Reference Citation Analysis]
5 Xu R, Choong PFM. Metastatic giant cell tumour of bone: a narrative review of management options and approaches. ANZ J Surg 2022. [PMID: 35143093 DOI: 10.1111/ans.17520] [Reference Citation Analysis]
6 Fang J, Zhu H, Xu P, Jiang R. Zingerone suppresses proliferation, invasion, and migration of hepatocellular carcinoma cells by the inhibition of MTDH-mediated PI3K/Akt pathway. J Recept Signal Transduct Res 2021;:1-9. [PMID: 34645355 DOI: 10.1080/10799893.2021.1988970] [Reference Citation Analysis]
7 Lin B, Zhu J, Yin G, Liao M, Lin G, Yan Y, Huang D, Lu S. Transcription Factor DLX5 Promotes Hair Follicle Stem Cell Differentiation by Regulating the c-MYC/microRNA-29c-3p/NSD1 Axis. Front Cell Dev Biol 2021;9:554831. [PMID: 34336814 DOI: 10.3389/fcell.2021.554831] [Reference Citation Analysis]
8 Palmini G, Brandi ML. microRNAs and bone tumours: Role of tiny molecules in the development and progression of chondrosarcoma, of giant cell tumour of bone and of Ewing's sarcoma. Bone 2021;149:115968. [PMID: 33892177 DOI: 10.1016/j.bone.2021.115968] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Zeng D, Xiao Z, Xu Q, Luo H, Wen L, Tang C, Shan Y, Tian J, Wei J, Li Y. Norcantharidin protects against renal interstitial fibrosis by suppressing TWEAK-mediated Smad3 phosphorylation. Life Sci 2020;260:118488. [PMID: 32979359 DOI: 10.1016/j.lfs.2020.118488] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
10 Zhou J, Ren Y, Tan L, Song X, Wang M, Li Y, Cao Z, Guo C. Norcantharidin: research advances in pharmaceutical activities and derivatives in recent years. Biomed Pharmacother. 2020;131:110755. [PMID: 33152920 DOI: 10.1016/j.biopha.2020.110755] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
11 Pan MS, Cao J, Fan YZ. Insight into norcantharidin, a small-molecule synthetic compound with potential multi-target anticancer activities. Chin Med 2020;15:55. [PMID: 32514288 DOI: 10.1186/s13020-020-00338-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
12 He Q, Xue S, Tan Y, Zhang L, Shao Q, Xing L, Li Y, Xiang T, Luo X, Ren G. Dual inhibition of Akt and ERK signaling induces cell senescence in triple-negative breast cancer. Cancer Lett 2019;448:94-104. [PMID: 30742942 DOI: 10.1016/j.canlet.2019.02.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
13 Li S, Chen P, Yang Q. Denosumab versus zoledronic acid in cases of surgically unsalvageable giant cell tumor of bone: A randomized clinical trial. J Bone Oncol 2019;15:100217. [PMID: 30740297 DOI: 10.1016/j.jbo.2019.100217] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]